Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy
Authors:
Open Access
- 1 January 2017
- journal article
- research article
- Published by SAGE Publications in Clinical Medicine Insights: Cardiology
- Vol. 11
Abstract
Transthyretin cardiomyopathy (TTR-CM) is a progressive, fatal disease caused by the accumulation of misfolded transthyretin (TTR) amyloid fibrils in the heart. Tafamidis is a kinetic stabilizer of TTR that inhibits misfolding and amyloid formation. In this post hoc analysis, data from an observational study (Transthyretin Amyloidosis Cardiac Study; n = 29) were compared with an open-label study of tafamidis in patients with TTR-CM (Fx1B-201; n = 35). To ensure comparable baseline disease severity, patients with New York Heart Association (NYHA) functional classification ≥III were excluded in this time-to-mortality analysis. Patients with either wild-type or Val122Ile genotypes treated with tafamidis have a significantly longer time to death compared with untreated patients (P = .0004). Similar results were obtained when limiting the analysis to wild-type patients only, without restricting NYHA functional classification (P = .0262). These results support earlier conclusions suggesting that tafamidis slows disease progression compared with no treatment outside of standard of care and warrant further investigation. ClinicalTrials.gov, NCT00694161.Keywords
This publication has 15 references indexed in Scilit:
- Senile Systemic Amyloidosis: Clinical Features at Presentation and OutcomeJournal of the American Heart Association, 2013
- Transthyretin (TTR) Cardiac AmyloidosisCirculation, 2012
- Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS)American Heart Journal, 2012
- Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascadeProceedings of the National Academy of Sciences, 2012
- Tafamidis Stabilizes Transthyretin and Improves Clinical Outcomes in Transthyretin Amyloid CardiomyopathyJournal of Cardiac Failure, 2011
- Clinical features and survival in senile systemic amyloidosis: comparison to familial transthyretin cardiomyopathyAmyloid, 2011
- Systemic Cardiac AmyloidosesCirculation, 2009
- Variant-Sequence Transthyretin (Isoleucine 122) in Late-Onset Cardiac Amyloidosis in Black AmericansNew England Journal of Medicine, 1997
- Systemic senile amyloidosis. Identification of a new prealbumin (transthyretin) variant in cardiac tissue: immunologic and biochemical similarity to one form of familial amyloidotic polyneuropathy.Journal of Clinical Investigation, 1989
- Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agentsThe American Journal of Cardiology, 1985